Neurosense Therapeutics Ltd Market Cap ($15.14 Million)
Market Cap & Net Worth: Neurosense Therapeutics Ltd (NRSN)
Neurosense Therapeutics Ltd market cap. Neurosense Therapeutics Ltd (NASDAQ:NRSN) has a market capitalization of $15.14 Million ($15.14 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25825 globally and #5440 in its home market, demonstrating a -18.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurosense Therapeutics Ltd's stock price $1.99 by its total outstanding shares 37766098 (37.77 Million). Also see NRSN cash flow conversion for how efficiently the company converts equity into cash flow.
Neurosense Therapeutics Ltd Market Cap History (2021–2026)
Neurosense Therapeutics Ltd market cap history from 2021 to 2026. Data shows change from $92.90 Million to $54.01 Million (-13.47% CAGR). Check today's stock price for Neurosense Therapeutics Ltd for real-time trading data and today's change.
Index Memberships
Neurosense Therapeutics Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #715 of 976 |
|
NASDAQ Composite
IXIC
|
$39.98 Trillion | 0.00% | #2363 of 3165 |
Weight: Neurosense Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neurosense Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurosense Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Neurosense Therapeutics Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NRSN by Market Capitalization
Companies near Neurosense Therapeutics Ltd in the global market cap rankings as of November 3, 2026. Also see Neurosense Therapeutics Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Neurosense Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Neurosense Therapeutics Ltd (2021–2026)
Market capitalization of Neurosense Therapeutics Ltd from 2021 to today. Between 2021 and today, Neurosense Therapeutics Ltd's market cap moved from $92.90 Million to $ 54.01 Million, with a yearly change of -13.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $54.01 Million | +85.96% |
| 2025 | $29.04 Million | -35.92% |
| 2024 | $45.32 Million | +52.87% |
| 2023 | $29.65 Million | -35.66% |
| 2022 | $46.07 Million | -50.41% |
| 2021 | $92.90 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Neurosense Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.14 Million USD |
| MoneyControl | $15.14 Million USD |
| MarketWatch | $15.14 Million USD |
| marketcap.company | $15.14 Million USD |
| Reuters | $15.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more